Stating that your company has tech it does not have in order to lure investors and obtain contracts would be fraud. Whether that's in fact the case with Theranos will become clear eventually.
Yes, operating under the assumption early stage rounds were predicated on the technology existing and being sufficiently robust to carry out a certain percent of tests, that would be fraud.